QSI
Quantum-Si incorporated
NASDAQ · Healthcare · Biotechnology · US
$0.77
+1.24%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.7x
Market Cap
$168.63M
MomentumView details →
1D Return
+1.24%
YTD Return
−30.24%
RSI (14)
47.0
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.7x
Market Cap
$168.63M
RSI (14)
47.0
MomentumView details →
1D Return
+1.24%
YTD Return
−30.24%
SummaryUpdated Jun 1, 2026
Quantum-Si Incorporated (NASDAQ:QSI) is a biotechnology company founded in 2013 and headquartered in Guilford, Connecticut. The company went public in November 2020 through a SPAC merger. Quantum-Si has developed what it claims to be the world's first single-molecule protein sequencing platform, representing a breakthrough in proteomics research. The company transitioned from a pre-revenue research and development stage to commercial operations in late 2022 with the launch of its flagship Platinum protein sequencing system. As of 2025, Quantum-Si is in the early stages of commercializing its technology across academic, biotechnology, and pharmaceutical markets globally.
Similar companies
Latest newsMore news →
Quantum-Si announced a targeted workforce reduction of about 20% to lower cash burn and fund the revised development timeline.22d agoQuantum-Si moved the planned launch of its Proteus protein sequencing platform to Q2 2027 from end of 2026, citing the need for an additional integrated instrument design cycle before production.22d agoQuantum-Si Incorporated reported a Q2 loss of $0.11 per share, beating the Zacks Consensus Estimate of a $0.13 loss and improving from a $0.16 loss a year ago.22d ago